Iodide

Iodide

SCHEMBL4994541

CC(C)(C)NCc1ccccc1.I

nearest known ligand 0.95

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACHECHRM1CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNG

The experimentally established mechanism targets of Iodide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 3/20 0.50
MAPT P10636 2/20 0.50
KDM4E B2RXH2 1/20 0.50
IDO1 P14902 2/20 0.46
THRB P10828 1/20 0.46
MEN1 O00255 1/20 0.46
KMT2A Q03164 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
LTA4H P09960 1/20 0.45
CYP2D6 P10635 2/20 0.45
LMNA P02545 2/20 0.45
RIPK1 Q13546 1/20 0.44
ATM Q13315 1/20 0.44
SLC6A2 P23975 1/20 0.43
TAAR1 Q96RJ0 1/20 0.43
CYP2C9 P11712 1/20 0.42
CYP2C19 P33261 1/20 0.42
HTT P42858 1/20 0.42
SIGMAR1 Q99720 1/20 0.42
RAB9A P51151 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL125129 0.98 CYP3A4 (0.52) CYP3A4MAPTKDM4EIDO1THRB
Water SCHEMBL13583453 0.95 CYP3A4 (0.56) CYP3A4MAPTKDM4EIDO1THRB
Hydrochloric Acid SCHEMBL538794 0.95 CYP3A4 (0.56) CYP3A4MAPTKDM4EIDO1THRB
Bromide SCHEMBL11038149 0.95 CYP3A4 (0.50) CYP3A4MAPTKDM4EIDO1THRB
SCHEMBL5839383 0.85 LTA4H (0.46) CYP3A4MAPTKDM4ELTA4HLMNA
SCHEMBL13958950 0.85 RAB9A (0.59) MAPTIDO1MEN1KMT2ALTA4H
SCHEMBL13958852 0.81 BCHE (0.69) MAPTMEN1KMT2ALMNAATM
SCHEMBL14145021 0.81 CYP3A4 (0.50) CYP3A4MAPTKDM4EIDO1THRB
SCHEMBL14433569 0.81 PRMT6 (0.42) CYP3A4MAPTKDM4EKMT2ALTA4H
SCHEMBL11811445 0.80 ATM (0.51) CYP3A4MAPTKDM4EIDO1THRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122069876-A Double-passivation flexible perovskite solar cell and preparation method thereof 合肥工业大学 2026-05-19 CN claimed
CN-114583059-B Perovskite solar cell with bias electrode 华碧光能科技(苏州)有限公司 2024-02-13 CN claimed
CN-114583059-A Perovskite solar cell with bias electrode 华碧新能源技术研究(苏州)有限公司 2022-06-03 CN claimed
CN-122069876-A Double-passivation flexible perovskite solar cell and preparation method thereof 合肥工业大学 2026-05-19 CN disclosed
CN-122069876-A Double-passivation flexible perovskite solar cell and preparation method thereof 合肥工业大学 2026-05-19 CN disclosed
CN-114583059-B Perovskite solar cell with bias electrode 华碧光能科技(苏州)有限公司 2024-02-13 CN disclosed
CN-114759142-A Four-terminal laminated perovskite solar cell 华碧新能源技术研究(苏州)有限公司 2022-07-15 CN disclosed
CN-114744119-A Two-end laminated perovskite solar cell 华碧新能源技术研究(苏州)有限公司 2022-07-12 CN disclosed
CN-114583059-A Perovskite solar cell with bias electrode 华碧新能源技术研究(苏州)有限公司 2022-06-03 CN disclosed
US-20080171756-A1 N-Substituted Glycine Derivatives: Prolyl Hydroxylase Inhibitors SMITHKLINE BEECHAM CORPORATION 2008-07-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080171756-A1 N-Substituted Glycine Derivatives: Prolyl Hydroxylase Inhibitors HIF1AN, EGLN2, EGLN3 CYP3A4 1362/4885MAPT 4781/4885KDM4E 746/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.